Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Narrative)

v3.21.2
Commitments and Contingencies (Details Narrative) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2021
Sep. 30, 2020
Sep. 30, 2021
Sep. 30, 2020
Operating lease expense $ 13,466 $ 13,462 $ 41,499 $ 41,565
Description of study drug and supplemental financial support     The Company will provide study drug and supplemental financial support for the clinical trial estimated to average approximately $2 million to $3 million per year.  
Operating lease monthly payment     $ 4,487  
XOMA Ltd        
Option and license agreement description     that could reach up to $14.925 million if the Company achieves all milestones  
GEIS        
Clinical-related expenses $ 300,000 $ 400,000 $ 1,000,000.0 $ 600,000
Onxeo S.A        
Option and license agreement description     the option agreement includes clinical, regulatory, developmental and sales milestones that could reach up to $108 million if the Company achieves all milestones, and escalating royalties on net sales from 5% to 10%.  
Option and license agreement fee     $ 1,000,000